X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs SUN PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH SUN PHARMA STERLING BIOTECH/
SUN PHARMA
 
P/E (TTM) x -0.3 37.9 - View Chart
P/BV x 0.0 4.0 0.3% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 STERLING BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
SUN PHARMA
Mar-18
STERLING BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs11701 1.5%   
Low Rs3433 0.8%   
Sales per share (Unadj.) Rs26.8110.4 24.3%  
Earnings per share (Unadj.) Rs-15.011.0 -136.3%  
Cash flow per share (Unadj.) Rs-5.517.2 -31.7%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs54.9158.8 34.6%  
Shares outstanding (eoy) m267.872,399.26 11.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.1 5.0%   
Avg P/E ratio x-0.551.6 -0.9%  
P/CF ratio (eoy) x-1.332.9 -3.9%  
Price / Book Value ratio x0.13.6 3.5%  
Dividend payout %018.2 0.0%   
Avg Mkt Cap Rs m1,8621,360,021 0.1%   
No. of employees `0001.417.8 7.6%   
Total wages/salary Rs m54753,671 1.0%   
Avg. sales/employee Rs Th5,303.314,890.9 35.6%   
Avg. wages/employee Rs Th403.83,017.1 13.4%   
Avg. net profit/employee Rs Th-2,959.01,480.6 -199.9%   
INCOME DATA
Net Sales Rs m7,181264,895 2.7%  
Other income Rs m438,388 0.5%   
Total revenues Rs m7,223273,282 2.6%   
Gross profit Rs m94756,081 1.7%  
Depreciation Rs m2,54314,998 17.0%   
Interest Rs m4,3775,176 84.6%   
Profit before tax Rs m-5,93144,295 -13.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m-1,9248,452 -22.8%   
Profit after tax Rs m-4,00726,338 -15.2%  
Gross profit margin %13.221.2 62.3%  
Effective tax rate %32.419.1 170.0%   
Net profit margin %-55.89.9 -561.2%  
BALANCE SHEET DATA
Current assets Rs m14,335316,359 4.5%   
Current liabilities Rs m49,809198,643 25.1%   
Net working cap to sales %-494.044.4 -1,111.7%  
Current ratio x0.31.6 18.1%  
Inventory Days Days40395 425.4%  
Debtors Days Days171108 158.5%  
Net fixed assets Rs m55,432213,178 26.0%   
Share capital Rs m2682,399 11.2%   
"Free" reserves Rs m13,935378,606 3.7%   
Net worth Rs m14,701381,006 3.9%   
Long term debt Rs m9,47817,721 53.5%   
Total assets Rs m73,988643,028 11.5%  
Interest coverage x-0.49.6 -3.7%   
Debt to equity ratio x0.60 1,386.1%  
Sales to assets ratio x0.10.4 23.6%   
Return on assets %0.54.9 10.2%  
Return on equity %-27.36.9 -394.2%  
Return on capital %-6.410.0 -64.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86040,816 4.6%   
Fx outflow Rs m2530,143 0.1%   
Net fx Rs m1,83510,673 17.2%   
CASH FLOW
From Operations Rs m1,71939,072 4.4%  
From Investments Rs m-3,148-33,708 9.3%  
From Financial Activity Rs m1,426-15,393 -9.3%  
Net Cashflow Rs m-3-7,359 0.0%  

Share Holding

Indian Promoters % 33.9 63.7 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.1 -  
FIIs % 9.9 23.0 43.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 8.3 473.5%  
Shareholders   21,482 133,026 16.1%  
Pledged promoter(s) holding % 55.9 0.5 10,554.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Sep 24, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS